Printer Friendly

CAMBRIDGE NEUROSCIENCE GAINS ADDITIONAL NIH GRANT FOR STUDY OF COMPOUNDS TO PREVENT NEUROLOGICAL DAMAGE

 CAMBRIDGE NEUROSCIENCE GAINS ADDITIONAL NIH GRANT
 FOR STUDY OF COMPOUNDS TO PREVENT NEUROLOGICAL DAMAGE
 CAMBRIDGE, Mass., Dec. 19 /PRNewswire/ -- Cambridge NueroScience Inc. (NASDAQ: CNSI) announced today that it has been awarded a Phase I Small Business Innovation Research (SBIR) grant from the NIH to identify novel calcium antagonists that block neurotransmitter release. Such compounds could prevent neurological damage during stroke, traumatic brain injury, and coronary artery bypass surgery. This lastest grant enhances the company's expanded research program in ion channel modulators, and brings to a total of 12 the grants that CNSI has received from NIH. The company has received over $1 million in grant revenues in 1991.
 There are an estimated 500,000 Americans who suffer from strokes each year, and another 500,000 who suffer severe traumatic injuries to the head or spinal cord. In addition, major surgical procedures, such as corornary artery bypass surgery, pose the risk of brain injury from complications associated with inadequate cerebral blood flow or small blood clots. There are currently no available drugs to limit or reduce the degree of neurological damage caused by these events.
 Cambridge NeuroScience is engaged in the discovery and development of proprietary pharmaceutical products to treat a variety of severe neurological and psychiatric disorders in three areas: neuroprotective and traumatic brain injury; novel antipsychotic compounds for the treatment of mental illnesses such as schizophrenia; and growth factors for the treatment of neurodegenerative diseases such as diabetic peripheral neuropathies and amyotrophic lateral sclerosis (Lou Gehrig's disease). As a complement to its antipsychotic products, the company is developing pramiracetam as an adjunct in the treatment of severe depression.
 -0- 12/19/91
 /CONTACT: Dr. Elkan Gamzu, chief operating officer of Cambridge NeuroScience, Inc., 617-225-0600; or Marcia A. Kean, executive VP of Feinstein Partners, Inc., 617-577-8110 for Cambridge NeuroScience/
 (CNSI) CO: Cambridge NeuroScience, Inc. ST: Massachusetts IN: MTC SU:


DD-Dh -- NE009 -- 3894 12/19/91 12:14 EST
COPYRIGHT 1991 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1991 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Dec 19, 1991
Words:318
Previous Article:WELLS FARGO 'A/F-1' LOC-BACKED ISSUES REMOVED FROM FITCHALERT -- FITCH FINANCIAL WIRE --
Next Article:MASTERCARD INTERNATIONAL ENACTS NEW POLICY PROHIBITING 900 NUMBER OFFERS OF ITS CARDS
Topics:


Related Articles
VERTEX PHARMACEUTICALS RECEIVES NIH GRANT FOR IMMUNOSUPPRESSIVE DRUG RESEARCH
CAMBRIDGE NEUROSCIENCE BEGINS HUMAN CLINICAL TRIALS OF NOVEL ANTI-STROKE COMPOUND
CAMBRIDGE NEUROSCIENCE AWARDED PHASE II SBIR GRANT FOR SIXTH TIME; GRANT AWARDED TO FURTHER RESEARCH IN ION-CHANNEL BLOCKERS
CAMBRIDGE NEUROSCIENCE REPORTS FIRST QUARTER RESULTS
CAMBRIDGE NEUROSCIENCE REPORTS SECOND QUARTER 1993 RESULTS IN LINE WITH EXPECTATIONS; STRENGTHENS CLINICAL DEVELOPMENT TEAM
CAMBRIDGE NEUROSCIENCE REPORTS FIRST QUARTER 1994 RESULTS; CERESTAT(TM) SAFETY STUDIES ON SCHEDULE; EFFICACY TRIALS BEING PLANNED
CAMBRIDGE NEUROSCIENCE REPORTS SECOND QUARTER 1994 RESULTS
CAMBRIDGE NEUROSCIENCE REPORTS THIRD QUARTER 1994 RESULTS
CAMBRIDGE NEUROSCIENCE REPORTS FIRST QUARTER 1995 RESULTS
Repligen Reports Second Quarter 1998 Results

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters